Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01565
|
|||||
| Drug Name |
Enrofloxacin
|
|||||
| Synonyms |
Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacinum; Enrofloxacino; endrofloxicin; BAY VP 2674; Bay-Vp-2674; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; UNII-3DX3XEK1BN; N-Ethylciprofloxacin; Baytril (TN); ERFX; Enrofloxacin [USAN:BAN:INN]; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; HSDB 6952; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3DX3XEK1BN; Enrofloxacin (USAN/INN)
|
|||||
| Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H22FN3O3
|
|||||
| Canonical SMILES |
CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
|
|||||
| InChI |
InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
|
|||||
| InChIKey |
SPFYMRJSYKOXGV-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 93106-60-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 359.4 | Topological Polar Surface Area | 64.099 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
-0.2
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:35720
|
|||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT03575312) Pharmacokinetics of Enrofloxacin in Plasma and Urine | |||||
| 2 | Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther. 2006 Aug;29(4):279-87. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.